|
2025
|
Invention
|
Ruxolitinib formulation for reduction of itch in atopic dermatitis.
This disclosure relates to m... |
|
|
Invention
|
Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof.
This applicat... |
|
|
Invention
|
Systems, methods, and computer programs, for analyzing images of a portion of a person to detect ... |
|
|
Invention
|
Sustained-release dosage forms of ruxolitinib.
The present invention relates to sustained-releas... |
|
|
Invention
|
Aminopyrazine diol compounds as pi3k-y inhibitors.
This application relates to compounds of Form... |
|
|
Invention
|
Solid forms of jak inhibitor and process of preparing the same.
The present disclosure is relate... |
|
|
Invention
|
Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibito... |
|
|
Invention
|
New topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of... |
|
|
Invention
|
Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors.
The present application provides imida... |
|
|
Invention
|
Bicyclic ureas as kinase inhibitors.
The present application provides bicyclic urea compounds th... |
|
|
Invention
|
Immunomodulator compounds and methods of use.
Compositions and methods for inducing PD-L1 intern... |
|
|
Invention
|
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors.
This application relates to ... |
|
|
Invention
|
Processes for preparing kras inhibitors.
This disclosure provides efficient and scalable process... |
|
|
Invention
|
Jak1 pathway inhibitors for the treatment of prurigo nodularis.
This disclosure relates to JAK1 ... |
|
|
Invention
|
Sppl2a inhibitors.
The present disclosure relates to tricyclic compounds comprising a diazepinon... |
|
|
Invention
|
Sppl2a inhibitors. The present disclosure relates to tricyclic compounds comprising a diazepinone... |
|
|
Invention
|
Bipyrazole derivatives as jak inhibitors.
The present invention provides compounds of Formula I:... |
|
|
Invention
|
Heterocyclic compounds as immunomodulators.
Disclosed are compounds of Formula (I′), methods of ... |
|
|
Invention
|
Bicyclic heterocycles as mrgprx2 antagonists. The present disclosure relates to bicyclic heterocy... |
|
|
Invention
|
Processes for preparing jak inhibitors and related intermediate compounds.
The present invention... |
|
2024
|
Invention
|
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors.
The present disclosure relates... |
|
|
Invention
|
Fused bicyclic pyrimidones as wrn inhibitors.
The present application is concerned with bicyclic... |
|
|
Invention
|
Bicyclooctane kras inhibitors.
Disclosed are compounds of Formula (I), methods of using the comp... |
|
|
Invention
|
Bicyclooctane kras inhibitors. Disclosed are compounds of Formula (I), methods of using the compo... |
|
|
Invention
|
Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors.
The present application... |
|
|
Invention
|
Combination therapy comprising dgk inhibitors and pd-1/pd-l1 inhibitors. The present application ... |
|
|
Invention
|
Tricyclic triazolo compounds as dgk inhibitors. The present application provides tricyclic triazo... |
|
|
Invention
|
Tricyclic triazolo compounds as dgk inhibitors.
The present application provides tricyclic triaz... |
|
|
Invention
|
Combinations and uses thereof.
The present disclosure describes a pharmaceutical combination of ... |
|
|
Invention
|
Heterocyclylamines as pi3k inhibitors.
The present invention provides heterocyclylamine derivati... |
|
|
Invention
|
Tricyclic urea compounds as jak2 v617f inhibitors.
The present application provides tricyclic ur... |
|
|
Invention
|
Ruxolitinib for treating hidradenitis suppurativa (hs). This disclosure relates to methods for tr... |
|
|
Invention
|
Salts of tam inhibitors.
The present application provides salt forms of N-(4-(4-Amino-7-(1-isobu... |
|
|
Invention
|
Topical ruxolitinib foam.
The present disclosure is directed to foamable composition suitable fo... |
|
|
Invention
|
Imidaz0[1,2-a]pyrimidine-5(1 h)-ones as wrn inhibitors.
Disclosed are compounds of Formula (I) a... |
|
|
Invention
|
Imidaz0[1,2-a]pyrimidine-5(1 h)-ones having a covalent warhead at the 3-position as wrn inhibitor... |
|
|
Invention
|
Heterocyclic kinase inhibitors.
The present application provides naphthyridine and pyridopyridaz... |
|
|
Invention
|
Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor.
The present invention relates... |
|
|
Invention
|
Bicyclic heterocycles as mrgprx2 antagonists.
The present disclosure relates to bicyclic heteroc... |
|
|
Invention
|
Derivatives of an fgfr inhibitor.
The present disclosure relates to derivatives (e.g., hydroxyl,... |
|
|
Invention
|
Kras inhibitors.
Disclosed are compounds of Formula (I), methods of using the compounds for inhi... |
|
|
Invention
|
Tricyclic compounds as inhibitors of wrn.
Disclosed are compounds of Formula (I), methods of usi... |
|
|
Invention
|
Bicyclic compounds as inhibitors of wrn.
Disclosed are compounds of Formula (I), methods of usin... |
|
|
Invention
|
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment.
The present d... |
|
|
Invention
|
Tricyclic compounds as inhibitors of kras.
Disclosed are compounds of Formula I, methods of usin... |
|
2023
|
Invention
|
Bicyclic amine cdk12 inhibitors.
The present application provides bicyclic amines that are inhib... |
|
2010
|
G/S
|
Pharmaceutical preparations for use in the treatment of oncological, hematological and inflammato... |
